Literature DB >> 22835602

Hodgkin's lymphoma in adults.

William Townsend1, David Linch.   

Abstract

Management of Hodgkin's lymphoma continues to develop. Outcomes for patients with favourable-risk, early-stage disease are excellent, and serial reductions in intensity of treatment have been made to retain the excellent prognosis while reducing the late effects of treatment. Prognosis is also very good in advanced-stage disease but the rate of relapse is higher than in early-stage disease, and the optimum first-line treatment is unclear. Workers are investigating the role of functional imaging to assess whether treatment can be tailored according to response, with the most intensive therapies reserved for patients predicted to have poor outcomes. In this Seminar we critically appraise the management of Hodgkin's lymphoma in early-stage disease, advanced-stage disease, and at relapse, with a focus on late effects of treatment.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22835602     DOI: 10.1016/S0140-6736(12)60035-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  33 in total

1.  Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation.

Authors:  L Angenendt; C Schliemann; M Lutz; E Rebber; A B Schulze; M Weckesser; L Stegger; M Schäfers; C Groth; T Kessler; G Lenz; M Stelljes; W E Berdel
Journal:  Bone Marrow Transplant       Date:  2015-11-09       Impact factor: 5.483

Review 2.  Enhancing Adolescent and Young Adult Oncology Research Within the National Clinical Trials Network: Rationale, Progress, and Emerging Strategies.

Authors:  Aaron R Weiss; Craig R Nichols; David R Freyer
Journal:  Semin Oncol       Date:  2015-07-10       Impact factor: 4.929

3.  Pancreatic cancer risk after treatment of Hodgkin lymphoma.

Authors:  G M Dores; R E Curtis; F E van Leeuwen; M Stovall; P Hall; C F Lynch; S A Smith; R E Weathers; H H Storm; D C Hodgson; R A Kleinerman; H Joensuu; T B Johannesen; M Andersson; E J Holowaty; M Kaijser; E Pukkala; L Vaalavirta; S D Fossa; F Langmark; L B Travis; J F Fraumeni; B M Aleman; L M Morton; E S Gilbert
Journal:  Ann Oncol       Date:  2014-07-25       Impact factor: 32.976

4.  Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.

Authors:  Neetha Gandikota; Sidonie Hartridge-Lambert; Jocelyn C Migliacci; Joachim Yahalom; Carol S Portlock; Heiko Schöder
Journal:  Cancer       Date:  2015-03-04       Impact factor: 6.860

5.  18F-FDG PET/MRI in patients suffering from lymphoma: how much MRI information is really needed?

Authors:  Julian Kirchner; Cornelius Deuschl; Johannes Grueneisen; Ken Herrmann; Michael Forsting; Philipp Heusch; Gerald Antoch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-04       Impact factor: 9.236

Review 6.  Ophthalmic Manifestations of Hodgkin Lymphoma: A Review.

Authors:  Juan Valenzuela; Jose J Echegaray; Emilio Dodds; Shree K Kurup; Careen Lowder; Sarah L Ondrejka; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2021-08-17

7.  Intrathoracic infections in Hodgkin lymphoma (HL) patients may cooperate with HL to trigger hemophagocytic lymphohistiocytosis: A retrospective study.

Authors:  Ji-Cheng Zhou; Bin-Bin Tan; Yan Huang; Yin-Ying Wu; Zhen-Jie Bai; Min-Lan Liang; Wei-Hua Zhao
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

8.  Stomach cancer risk after treatment for hodgkin lymphoma.

Authors:  Lindsay M Morton; Graça M Dores; Rochelle E Curtis; Charles F Lynch; Marilyn Stovall; Per Hall; Ethel S Gilbert; David C Hodgson; Hans H Storm; Tom Børge Johannesen; Susan A Smith; Rita E Weathers; Michael Andersson; Sophie D Fossa; Michael Hauptmann; Eric J Holowaty; Heikki Joensuu; Magnus Kaijser; Ruth A Kleinerman; Frøydis Langmark; Eero Pukkala; Leila Vaalavirta; Alexandra W van den Belt-Dusebout; Joseph F Fraumeni; Lois B Travis; Berthe M Aleman; Flora E van Leeuwen
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

9.  [Extranodal manifestation of classical Hodgkin lymphoma in the head and neck region].

Authors:  H-U Völker; E Becker; H-K Müller-Hermelink; M Scheich
Journal:  HNO       Date:  2020-01       Impact factor: 1.284

10.  Simultaneous occurrence of Hodgkin's lymphoma and multiple myeloma: A case report and review of the literature.

Authors:  Chen Huang; Guimin Zhao; Lianjing Wang; Huichao Zhang; Xiaolin Wu; Mingzeng Zhang; Ruijuan Ma; Ling Wang; Yueping Liu; Lihong Liu
Journal:  Oncol Lett       Date:  2016-04-27       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.